What the evidence shows for ibogaine in alcohol use disorder — smaller than the opioid signal, real cardiac risk, and what to know before booking a clinic.
Ibogaine for alcoholism is one of the most-asked questions we get about this substance, and it deserves a careful answer. The evidence base is smaller than for opioids, but it is not zero. Animal models, observational reports from Mexican clinics, and the shared neuropharmacology of addiction all support the idea that ibogaine treatment for alcohol dependence can reduce craving and reset the reward system.
What ibogaine for alcohol addiction does not yet have is a completed randomized controlled trial. That matters because a different psychedelic — psilocybin — does have controlled evidence in alcohol use disorder. This guide walks through what the science actually says, how ibogaine compares to psilocybin and naltrexone, the cardiac and withdrawal risks that are unique to alcohol patients, and what treatment at a legitimate clinic actually looks like.
The evidence for ibogaine treatment for alcohol dependence rests on three legs: animal studies, observational clinic reports, and extrapolation from the opioid literature. No completed randomized controlled trial in AUD exists.
Animal models. Rezvani and colleagues, working with alcohol-preferring rat strains in the 1990s and 2000s, reported that single doses of ibogaine reduced voluntary ethanol intake by 50% or more for several days. He, McKenna, and other groups documented similar reductions in cue-induced relapse. The active metabolite noribogaine, with its long half-life, is thought to drive most of the post-dose effect.
Observational reports. Mash and colleagues at the Freedom Centers program (Frontiers in Pharmacology, 2018) enrolled opioid and cocaine patients, but a subset had co-occurring AUD. Reported reductions in craving extended to alcohol in that subgroup. Clinic surveys from Beond, Ambio, and Crossroads have described similar signals, though none have published peer-reviewed AUD-specific outcomes.
No RCT yet. The Ona et al. (2023) systematic review in Drug and Alcohol Dependence catalogued the full ibogaine literature and noted the AUD signal as promising but unproven. Texas's IMPACT consortium, funded in 2025, is expected to include an AUD arm, but results are years away.
Ibogaine's mechanism is unusually broad, and several of its actions are directly relevant to alcohol use disorder. It is not a single receptor drug like naltrexone.
Ibogaine vs psilocybin for alcoholism is the most useful comparison most patients can make, because both are single-dose or short-course psychedelic interventions with anti-craving profiles. Naltrexone is included as the standard-of-care pharmaceutical benchmark. The table summarizes the practical differences.
| Factor | Ibogaine | Psilocybin | Naltrexone |
|---|---|---|---|
| Evidence base in AUD | Animal + observational; no RCT | Positive Phase 2 RCT (Bogenschutz 2022) | Multiple RCTs; FDA-approved |
| Session length | 24–36 hours | 6–8 hours | Daily pill or monthly injection |
| Cardiac risk | High — QT prolongation, torsades reported | Low — transient BP/HR increase | Low |
| Detox required first | Yes — medically supervised | Yes — medically supervised | Yes — must be opioid-free too |
| Ongoing daily use | No — single flood dose | No — 1–3 sessions | Yes — daily or monthly |
| Typical cost | $5,000–$15,000 abroad | $3,000–$10,000 at legal retreats | $30–$1,300/month with insurance |
| Access | Mexico, Costa Rica, Netherlands | Oregon, Colorado, Jamaica, Netherlands | Any US prescriber |
When to choose ibogaine. Ibogaine makes the most sense when someone has already failed psilocybin therapy, naltrexone, and structured programs, and is drawn to the deeper introspective profile of a 24–36 hour experience. It is a reasonable choice for patients with a co-occurring opioid problem, where ibogaine's evidence is strongest. For a first-time psychedelic approach to alcoholism with the strongest published data, most experts would point to psilocybin first.
Cardiac safety is the single most important variable when considering ibogaine for alcoholism. Ibogaine prolongs the QT interval on the electrocardiogram, and prolonged QT can trigger torsades de pointes and sudden cardiac death. The literature includes at least 33 reported deaths, almost all in unregulated settings.
Chronic heavy drinking makes this worse. Alcohol depletes magnesium and potassium, both of which are QT-sensitizing when low. Long-term alcohol use also causes alcoholic cardiomyopathy in some patients, which further raises arrhythmia risk. This is why any responsible program will require:
This section matters more for AUD than for any other indication. Alcohol withdrawal can be fatal — unlike opioid withdrawal, which is painful but not usually life-threatening. Seizures, delirium tremens, and cardiovascular collapse are real risks in heavy daily drinkers who stop abruptly.
Reputable ibogaine clinics will not accept an actively drinking patient. They require you to complete a medically managed detox first, typically using benzodiazepines on a taper, in a hospital or licensed detox facility. That process usually takes 5–10 days. Ibogaine dosing then happens after you are physiologically stable.
Operational reality most competitors don't surface. Because alcohol on board dramatically increases arrhythmia risk with ibogaine, most credible clinics enforce a documented sobriety window before dosing — commonly 72 hours minimum, verified with a breath alcohol test on arrival at the facility. Some also test urine for benzodiazepine metabolites from the detox taper. If a clinic does not test on arrival or does not require documented detox records, that is a safety red flag. Do not attempt an unsupervised detox at home so you can meet a booking date.
A legitimate ibogaine program for AUD is typically five to seven days on site, on top of a completed detox. The structure at well-established clinics looks similar to the opioid protocol described in our ibogaine for opioid addiction guide.
Cost for ibogaine treatment for alcoholism runs $5,000–$15,000 at established clinics in Mexico and Costa Rica. Pricing generally does not vary by primary indication — the same facility charges roughly the same for opioid, alcohol, or trauma programs. Our best ibogaine treatment centers guide reviews the seven most publicly documented facilities by cardiac protocol and medical credentials.
Ibogaine remains Schedule I in the United States, so no US clinic can legally administer it. Most patients travel to Baja California, Puerto Vallarta, San José del Cabo, or Costa Rica. The retreat finder lets you filter by indication, location, and price range.
Ibogaine is not the right choice for every AUD patient. The following are common exclusions at reputable clinics:
If any of these apply, psilocybin for AUD, naltrexone, or a combination of medication and structured therapy will usually be a safer starting point. Our psychedelic therapy for addiction hub compares options across substances.
Ibogaine for alcoholism is a serious option with a real mechanistic rationale and observational support, but the controlled evidence still favors psilocybin. Alcohol adds two safety layers on top of ibogaine's baseline cardiac risk: potentially fatal withdrawal and electrolyte-driven arrhythmia risk. If you pursue ibogaine, do it only through a clinic that requires documented medical detox, tests for alcohol on arrival, runs a magnesium-ibogaine protocol, and keeps a physician on site throughout. If any of those are missing, choose another path.
Next steps. Read our psilocybin for alcohol use disorder guide for the psychedelic option with the strongest published data. Compare specific facilities in our best ibogaine treatment centers guide. For a broader comparison of dissociative options, see ibogaine vs ketamine. And if you are looking at any option, filter clinics by protocol in the retreat finder.
The evidence for ibogaine in alcohol use disorder is smaller than the evidence for opioid use disorder but still meaningful. Animal models show ibogaine and its metabolite noribogaine reduce voluntary alcohol consumption and blunt cue-induced relapse. Observational data from Mexican clinics reports meaningful reductions in drinking days after a single flood dose. No randomized controlled trial for AUD has been completed, and psilocybin currently has stronger controlled evidence for this indication.
For controlled-trial evidence, psilocybin has the stronger case: Bogenschutz et al.'s 2022 JAMA Psychiatry trial reported 9.7% heavy drinking days over 32 weeks on psilocybin vs. 23.6% on active placebo — a 13.9-percentage-point difference (p=0.01) and roughly a 59% relative reduction. Ibogaine has no comparable AUD trial. Ibogaine may be considered when severe opioid or polysubstance dependence is present alongside alcohol, where its cross-addiction signal matters — but the cardiac risk profile is far higher than psilocybin's.
Programs at established Mexican and Costa Rican clinics typically run $5,000–$15,000 including cardiac screening, accommodation, the session, and integration support. Pricing is generally the same whether the primary indication is opioid or alcohol use disorder; there is no AUD-specific discount.
Yes, and this is medically critical. Alcohol withdrawal can be life-threatening, so most reputable clinics require a medically managed detox (in-patient or supervised outpatient) before the patient travels for ibogaine treatment. Do not attempt an unsupervised detox from heavy daily drinking — the risk of seizure and delirium tremens is real.
Get ibogaine research & policy updates
New trials, FDA decisions, and legal changes for ibogaine — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.